ArticleAging2019
LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- LHX2: a transcription factor in development, homeostasis, repair, and disease.Frontiers in cell and developmental biology · 2026Review
- Silencing long non-coding RNA linc00689 suppresses the growth and invasion of osteosarcoma cells by targeting miR-129-5p/NUSAP1.International journal of experimental pathology · 2025Article
- Whole-Genome Methylation Sequencing Analysis and Functional Verification of LIM-Homeobox Family Genes in Cervical Cancer.International journal of general medicine · 2025Article
- Article
- Treatment of chronic obstructive pulmonary disease by traditional Chinese medicine Morin monomer regulated by autophagy.Journal of thoracic disease · 2024Article
- Epigenetic Regulation of Autophagy in Bone Metabolism.Function (Oxford, England) · 2024Review
- LHX2 Is a Potential Biomarker and Associated with Immune Infiltration in Breast Cancer.Cancers · 2023Article
- Identifying novel regulators of placental development using time-series transcriptome data.Life science alliance · 2023Article
- FGF23 promotes proliferation, migration and invasion by regulating miR-340-5p in osteosarcoma.Journal of orthopaedic surgery and research · 2023Article
- LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis.British journal of cancer · 2022Article
- [RHPN2 is highly expressed in osteosarcoma cells to promote cell proliferation and migration and inhibit apoptosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Article
- Exploring the role of non-coding RNAs in autophagy.Autophagy · 2022Review
- Article
- Role of microRNA-129 in cancer and non-cancerous diseases (Review).Experimental and therapeutic medicine · 2021Review
- Conservation of Aging and Cancer Epigenetic Signatures across Human and Mouse.Molecular biology and evolution · 2021Article
- Effect ofTranslational cancer research · 2021Article
- iTRAQ-based proteomic analysis of the molecular mechanisms and downstream effects of fatty acid synthase in osteosarcoma cells.Journal of clinical laboratory analysis · 2021Article
- Aurora-B knockdown inhibits osteosarcoma metastasis by inducing autophagy via the mTOR/ULK1 pathway.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transcript factor LHX2 is dysregulated in many cancers but its role in osteosarcoma (OS) remains unclear. In this study, we confirm that LHX2 is up-regulated in osteosarcoma, and that its silencing inhibits OS malignancy and induces autophagy via mTOR signaling. We further demonstrate that miR-129-5p negatively regulates LHX2 and suppresses the malignant phenotypes of OS. LHX2 overexpression could restore the malignant phenotypes. In conclusion, LHX2 regulates tumorigenesis and autophagy via mTOR in OS and is negatively regulated by miR-129-5p. Targeting the miR-129-5p/LHX2/mTOR axis therefore represents a novel therapeutic strategy for OS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.